ESMO Breast 2022 | Biological behaviour of HER2-low BC is dependent on HR expression

Maria Fernanda Mosele, MD, Gustave Roussy, Villejuif, France, talk on HER2-low breast cancer as a new entity in categorizing breast cancer patients, which has yet to procure a standardized definition amongst. The biological behavior of HER2-low breast cancer is dependent on hormone receptor (HR) expression. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.